

F. No. ND/MA/23/000141
Government of India
Directorate General of Health Services
Central Drugs Standard Control Organization
(New Drugs Division)

FDA Bhawan, Kotla Road,
New Delhi-11 0002

Dated:

To
M/s Sun Pharmaceutical Industries Limited,
Tandalja, Vadodara, Gujarat—390012.

Subject: Application for permission to conduct " A Prospective, Multicenter, Randomized, Double-blind, Double-dummy, Parallel-group, Active controlled, Phase III Study to Evaluate the Efficacy and Safety of Eluxadoline in Comparison to Mebeverine for Treatment of Patients With Diarrhoea-Predominant Irritable Bowel Syndrome."-regarding.

Sir,

With reference to your application no. **ND/CT21/ BO/2023/38998** dated **08.08.2023**; please find enclosed herewith the permission in **Form CT-06, No. CT/ND/01/2024** to conduct the subject mentioned clinical trial under the provisions of New Drugs and Clinical Trial Rules, 2019.

This permission is subject to the conditions, as mentioned below.

RAJEEV SINGH
RAGHUVANSHI
|

Digitally signed by RAJEEV SINGH RAGHUVANSHI
DN: c=IN, o=CENTRAL DRUGS STANDARD
CONTROL ORGANIZATION, ou=RAJEEV SINGH
RAGHUVANSHI,
2.5.4.20=80c62f6a23e4efb8a239774cdeb03c276
9041015a06564fe67f54b765db1cb,
postalCode=600034, st=TAMIL NADU,
serialNumber=657F5E47D940985D8F038DC902D0
E1FE73CFA12A1A126EA94FA5701124A19013,
cn=RAJEEV SINGH RAGHUVANSHI
Date: 2024.01.19 17:28:12 +05'30'

(Dr. Rajeev Singh Raghuvanshi)
Central Licensing Authority

Conditions of permission

- (i) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licencing Authority under Rule 8;
- (ii) Where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of Rule 7:

Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:

Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;

- (iii) In case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;
- (iv) The Central Licencing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;
- (v) Clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;
- (vi) Clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;
- (vii) Status of enrolment of the trial subjects shall be submitted to the Central Licencing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;
- (viii) Six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licencing Authority;
- (ix) In case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licencing Authority within thirty working days of such termination;
- (x) Any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licencing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI of the New Drugs and Clinical Trials Rules, 2019;
- (xi) In case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with the Chapter VI of the said Rules and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of the receipt of order issued by Central Licencing Authority in *accordance* with the provisions of the said Chapter;
- (xii) In case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with the Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of receipt

of the order issued by the Central Licencing Authority in accordance with the provisions of the said Chapter;

- (xiii) The premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licencing Authority who may be accompanied by officers of the State Licencing Authority or outside experts as authorized by the Central Licencing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;
- (xiv) Where the New Drug or Investigational New Drug is found to be useful in clinical development, the sponsor shall submit an application to the Central Licencing Authority for permission to import or manufacture for sale or for distribution of new drug in India, in accordance with Chapter X of these rules, unless otherwise justified;
- (xv) The Laboratory owned by any person or a company or any other legal entity and utilized by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licencing Authority and may be used for test or analysis of any drug for and on behalf of Central Licencing Authority;
- (xvi) The Central Licencing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;
- (xvii) The sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.
- (xviii) Informed Consent Documents (ICD) viz. Patient Information Sheet (PIS) and Informed Consent Form (ICF) complete in all respect & must be got approved from the respective Ethics committee and submitted to CDSCO before enrolling first subject at the respective site.

FORM CT-06*(See rules 22, 25, 26, 29 and 30)***PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR
INVESTIGATIONAL NEW DRUG**

The Central Licensing Authority hereby permits **M/s Sun Pharmaceutical Industries Limited, Tandalja, Vadodara, Gujarat—390012. Tel. : (91-265) 661 5500 Fax : (91-265) 235 4897** to conduct clinical trial of the new drug as per Protocol Number: **ICR/23/002, Version No. 2.0 dated 31st October 2023** in the below mentioned clinical trials sites.

2. Details of new drug or investigational new drug and clinical trial site:

Names of the new drug or investigational new drug:	Eluxadoline Tablets 75 mg and 100 mg	
Therapeutic class:	Mu opioid receptor agonist	
Dosage form:	Tablets	
Composition:	Each film coated tablet contains: Eluxadoline.....75 mg or 100 mg Excipients..... q.s.	
Indications:	Indicated in adults for the treatment of irritable bowel syndrome with diarrhoea (IBS-D).	
Details of clinical trial sites-		
Sr. No.	Name of Principal Investigator & Trial Sites	Ethics Committee Name/ Registration Number
1.	Dr. Dawesh Prakash Yadav (HOD) Department of Gastroenterology, Institute of Medical Sciences, Varanasi	Institutional Ethics Committee, Institute of Medical Sciences, Varanasi ECR/526/Inst/UP/2014/RR-20
2.	Dr. P. Shravan Kumar (Professor and HOD) Department of Gastroenterology, Gandhi Hospital, Secunderabad	Institutional Ethics Committee, Gandhi Medical College and Hospital, Secunderabad ECR/180/Inst/AP/2013/RR-19
3.	Dr. Anumula Kavitha (Professor and HOD) Department of Gastroenterology, Government General Hospital, Guntur	Ethics Committee, Guntur Medical College, Guntur ECR/467/Inst/AP/2013/RR-19
4.	Dr Aravind K (Professor and HOD) Department of Gastroenterology, PMSSY Super Speciality Hospital, Hubli	Ethics Committee, Karnataka Institute of Medical Sciences, Hubli ECR/486/Inst/KA/2 013/RR-20
5.	Dr Konatham Rambabu (Professor and HOD)	Institutional Ethics Committee, Visakha Institute of Medical Sciences, Visakhapatnam

	Department of Medicine, Visakha Institute of Medical Sciences, Visakhapatnam	ECR/1421/Inst/AP/ 2020
6.	Dr Behera Anupama (Associate Professor) All India Institute of Medical Science, Bhubaneswar	Institutional Ethics Committee, AIIMS, Bhubaneswar ECR/534/Inst/OD/2 014/RR-20
7.	Dr Surendra Kumar (Senior Professor) Department of Medicine, SP Medical College & A.G. of Hospitals, Bikaner	Ethics Committee, S.P. Medical College, Bikaner ECR/27/SP/Inst/RJ/ 2013/RR-19
8.	Dr Gupta Dhaval Vinaykumar (Consultant Gastroenterology) Mission Gastro Hospital, Ahmedabad	Medilink Ethics Committee, Medilink Hospital Research Centre, Ahmedabad ECR/344/Inst/GJ/2013/RR-19
9.	Dr Agrawal Amitchand Fattechand (Director and Consultant Gastroenterology) LGI Hospital, Nagpur	Ethics Committee, Crescent Hospital Heart Centre, Nagpur ECR/682/Inst/MH/2014/RR-21
10.	Dr Mehta Vatsal Kirit Kumar (Consultant Gastroenterologist) Health 1 Super Speciality Hospital, Ahmedabad	Ethics Committee, Health 1 Super Speciality Hospital, Ahmedabad ECR/1666/Inst/GJ/2022
11.	Dr Nath Preetam (Associate Professor) Kalinga Institute of Medical Sciences (KIMS) Hospital, Bhubaneswar	Institutional Ethics Committee, Kalinga Institute of Medical Sciences, Bhubaneswar ECR/321/Inst/OR/2013/RR-20
12.	Dr Ganesh Muniappan (Chief Consultant Gastroenterologist) Ashwin Multispeciality Hospital, Coimbatore	Institutional Ethics Committee, Ashwin Hospital, Coimbatore ECR/1795/Inst/TN/2023

3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

**RAJEEV SINGH
RAGHUVANSHI**

Digitally signed by RAJEEV SINGH RAGHUVANSHI
DN: c=IN, o=CENTRAL DRUGS STANDARD CONTROL
ORGANIZATION, ou=RAJEEV SINGH RAGHUVANSHI,
2.5.4.20=80c52f6a23e4e1be8a239774cdeb03c276904
1015a06564fe67f54b765db1cb, postalCode=600034,
st=TAMIL NADU,
serialNumber=657f5e47d940985d8f03bdc902d0e1f
e73cfa12a1a126eA94FA5701124A19013, cn=RAJEEV
SINGH RAGHUVANSHI
Date: 2024.01.19 17:27:54 +05'30'

**(Dr. Rajeev Singh Raghuvanshi)
Central Licensing Authority
Stamp**

New Delhi
Date: